William Blair Has Bearish Estimate for CRBP Q3 Earnings

Key Points

• William Blair has downgraded its Q3 2025 earnings per share (EPS) estimate for Corbus Pharmaceuticals to ($1.46), significantly lower than the previous estimate of ($0.96).
• Despite a recent earnings report beating the consensus estimate, Corbus forecasted EPS declines for multiple future quarters, including FY2025 expected at ($5.81) and FY2026 at ($6.09).
• Analyst ratings for Corbus range from one sell to nine buy ratings, with a consensus target price of $49.00, reflecting mixed investor sentiment around the stock.

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Free Report) - Research analysts at William Blair dropped their Q3 2025 earnings per share estimates for Corbus Pharmaceuticals in a research report issued on Tuesday, August 5th. William Blair analyst A. Hsieh now anticipates that the biopharmaceutical company will post earnings of ($1.46) per share for the quarter, down from their previous estimate of ($0.96). The consensus estimate for Corbus Pharmaceuticals' current full-year earnings is ($4.23) per share. William Blair also issued estimates for Corbus Pharmaceuticals' Q4 2025 earnings at ($1.52) EPS, FY2025 earnings at ($5.81) EPS, Q1 2026 earnings at ($1.51) EPS, Q2 2026 earnings at ($1.49) EPS, Q3 2026 earnings at ($1.55) EPS, Q4 2026 earnings at ($1.54) EPS, FY2026 earnings at ($6.09) EPS and FY2027 earnings at ($7.42) EPS.

Other equities analysts have also issued reports about the company. Lifesci Capital raised Corbus Pharmaceuticals to a "strong-buy" rating in a research report on Saturday, July 12th. HC Wainwright reduced their price objective on Corbus Pharmaceuticals from $50.00 to $40.00 and set a "buy" rating for the company in a research note on Wednesday, May 7th. Oppenheimer reduced their price objective on Corbus Pharmaceuticals from $56.00 to $53.00 and set an "outperform" rating for the company in a research note on Wednesday. B. Riley upgraded Corbus Pharmaceuticals to a "strong-buy" rating and set a $28.00 price target for the company in a research note on Wednesday, July 30th. Finally, Royal Bank Of Canada cut their price target on Corbus Pharmaceuticals from $65.00 to $58.00 and set an "outperform" rating for the company in a research note on Wednesday, May 7th. One equities research analyst has rated the stock with a sell rating, nine have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $49.00.

Corbus Pharmaceuticals Price Performance

Shares of NASDAQ:CRBP traded down $0.57 during trading on Thursday, reaching $8.43. 86,797 shares of the stock were exchanged, compared to its average volume of 116,367. Corbus Pharmaceuticals has a 1-year low of $4.64 and a 1-year high of $61.89. The stock has a fifty day moving average of $8.48 and a two-hundred day moving average of $7.71. The firm has a market cap of $103.31 million, a price-to-earnings ratio of -1.77 and a beta of 3.20.

Corbus Pharmaceuticals (NASDAQ:CRBP - Get Free Report) last issued its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported ($1.44) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.55) by $0.11.

Hedge Funds Weigh In On Corbus Pharmaceuticals

A number of large investors have recently bought and sold shares of the stock. Wells Fargo & Company MN increased its stake in shares of Corbus Pharmaceuticals by 51.7% during the fourth quarter. Wells Fargo & Company MN now owns 6,444 shares of the biopharmaceutical company's stock valued at $76,000 after buying an additional 2,195 shares during the period. Corton Capital Inc. purchased a new position in shares of Corbus Pharmaceuticals during the second quarter valued at approximately $86,000. Deutsche Bank AG increased its stake in shares of Corbus Pharmaceuticals by 46.8% during the fourth quarter. Deutsche Bank AG now owns 8,206 shares of the biopharmaceutical company's stock valued at $97,000 after buying an additional 2,616 shares during the period. Aquatic Capital Management LLC purchased a new position in shares of Corbus Pharmaceuticals during the fourth quarter valued at approximately $101,000. Finally, Two Sigma Advisers LP purchased a new stake in Corbus Pharmaceuticals in the fourth quarter worth $130,000. 64.64% of the stock is owned by hedge funds and other institutional investors.

Corbus Pharmaceuticals Company Profile

Corbus Pharmaceuticals Holdings, Inc, a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity.